Price chart (1D to 10Y)
Licensed market data — shown to members, not published to the open web.
Valuation vs Instaport thresholds (P/E, PEG, P/FCF, P/S)
Licensed market data — shown to members, not published to the open web.
Profile
From SEC filingsCompany description
We are a clinical-stage, research and development biotechnology company focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. We have developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs and have two clinical candidates and six preclinical candidates currently in development. Clinical candidate mipletamig is a CD123xCD3 T cell engager currently being clinically evaluated in the RAINIER trail, part one of a Phase 1b/2 program initiated in August 2024 for the treatment of frontline acute myelogenous leukemia (AML) in combination with standard of care venetoclax + azacitidine. Clinical candidate ALG.APV-527 targets 4-1BB (co-stimulatory receptor) and 5T4 (tumor antigen). The compound is designed to reactivate antigen-primed T cells to specifically kill tumor cells and is currently being evaluated for the treatment of multiple solid tumor types, potentially including breast, cervical, non-small- cell-lung, prostate, renal, gastric, colorectal and bladder cancers. Along with our two clinical candidates, we have six preclinical candidates. All eight molecules were developed using our proprietary ADAPTIR and ADAPTIR-FLEX protein technology platforms. We wholly own both platforms. This enables us to efficiently design and create new molecules and support long-term growth. Based on the safety and tolerability results from mipletamig, which utilizes a unique and proprietary CRIS-7 binding domain, the Company has built out its CD3 engaging portfolio to five molecules.
Read the full filing description · filed 26 Mar 2026
At a glance
- Sector
- Healthcare
Source: SEC filings. Information and analytics, not investment advice.